Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications

References

• Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–160.
   PubMed Web of Science ®Google Scholar
• Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem. 2009;16:3152–3167.
   PubMed Web of Science ®Google Scholar
• Andoh A, Yagi Y, Shioya M, et al. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol. 2008;14:5154–5161.
   PubMed Web of Science ®Google Scholar
• Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362–381.
   PubMed Web of Science ®Google Scholar
• Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–374.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49–62.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.
   PubMedGoogle Scholar
• Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015;165:270–282.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405–417.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. The rise of the biosimilar. Expert Rev Clin Pharmacol. 2012;5:597–599.
   PubMed Web of Science ®Google Scholar
• Pentek M, Zrubka Z, Gulacsi L. The economic impact of biosimilars on chronic immune-mediated inflammatory diseases. Curr Pharm Des. 2017. DOI:10.2174/1381612824666171129193708. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Charles D, Loaiza-Bonilla A. The role of biosimilars in patient access to therapeutic antibodies for immune mediated inflammatory diseases. Curr Pharm Des. 2017. DOI:10.2174/1381612824666171129192607. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Kálmán-Szekeres Z, Olajos M, Ganzler K. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal. 2012;69:185–195.
   PubMed Web of Science ®Google Scholar
• Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–5117.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013;5:621–623.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance – non-clinical and clinical issues. Committee for Medicinal Products for Human Use (CHMP); 2015 [cited 2016 Jan 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
   Google Scholar
• Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther. 2017;11:1509–1515.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3:209–217.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for Industry. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2015 [cited 2016 Jan 26]. Available from: www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
   Google Scholar
• Vande Casteele N, Sandborn WJ. Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015;12(7):373–374.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–1257.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Van Stappen T, Jairath V, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42(10):1158–1169.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. 2017;11(1):26–34.
   Google Scholar
• Humira [package insert]. Chicago, IL: Food and Drug Administration; 2017.
   Google Scholar
• Humira [summary of product characteristics]. European Medicines Agency; 2017.
   Google Scholar
• Bui LA, Hurst S, Finch GL, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015;20(Suppl 1):3–15.
   PubMed Web of Science ®Google Scholar
• Jauch-Lembach J, Skerjanec A, Haliduola H, et al. Randomized, double-blind, single-dose, three-arm parallel trial to determine the pharmacokinetics and safety of GP2017, EU- and US-adalimumab in healthy male subjects. Arthritis Rheumatol. 2017;69(suppl 10):Abstract2443.
   Google Scholar
• Blauvelt A, Fowler J Jr., Schuck E, et al. A randomized, double-blind, multicenter study to compare the efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (GP2017) with originator adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. J Am Acad Dermatol. 2017;76(6)(suppl1):AB22.
   Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–3725.
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025–4031.
   PubMed Web of Science ®Google Scholar
• Douni E, Sfikakis PP, Douni E, et al. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther. 2004;6:R65–R72.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–6604.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
   PubMed Web of Science ®Google Scholar
• Tebbey PW, Varga A, Naill M, et al. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs. 2015;7(5):805–811.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14(12):1685–1696.
   PubMed Web of Science ®Google Scholar
• Giragossian C, Clark T, Piché-Nicholas N, et al. Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. Curr Drug Metab. 2013;14(7):764–790.
   PubMed Web of Science ®Google Scholar
• Challa DK, Velmurugan R, Ober RJ, et al. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Curr Top Microbiol Immunol. 2014;382:249–272.
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12(1):33–43.
   PubMed Web of Science ®Google Scholar
• Glassman PM, Abuqayyas L, Balthasar JP. Assessments of antibody biodistribution. J Clin Pharmacol. 2015;55(Suppl S3):S29–S38.
   PubMed Web of Science ®Google Scholar
• Bessis N, Decker P, Assier E, et al. Arthritis models: usefulness and interpretation. Semin Immunopathol. 2017;39:469–486.
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Hijazi Y, Luttringer O, et al. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica. 2007;37:1331–1354.
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Tannenbaum S, Wu K, et al. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010;106:195–209.
   PubMed Web of Science ®Google Scholar
• McLennan DN, Porter CJ, Charman SA. Drug Discov Today Technol. 2005;2(1):89–96.
   PubMedGoogle Scholar
• Wasan SK, Kane SV. Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011;5:679–684.
   PubMed Web of Science ®Google Scholar
• Danese S. Adalimumab in ulcerative colitis: ready for prime time. Dig Liver Dis. 2013;45:8–13.
   PubMedGoogle Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.
   PubMed Web of Science ®Google Scholar
• Tsuruta LR, Lopes Dos Santos M, Moro AM. Biosimilar advancements: moving on to the future. Biotechnol Prog. 2015;31(5):1139–1149.
   PubMed Web of Science ®Google Scholar